Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

International Journal of Cardiology

Volumn 77, Issue 2-3, 2001, Pages 247-253

  Musial, Jacek ^a   Undas, Anetta ^a   Gajewski, Piotr ^a   Jankowski, Milosz ^a   Sydor, Wojciech ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Aspirin; C reactive protein; Hypercholesterolemia; Proinflammatory cytokines; Simvastatin

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; INTERLEUKIN 6; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICHOLESTEREMIC AGENTS; ASPIRIN; C-REACTIVE PROTEIN; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035138445     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00439-3     Document Type: Article

References (30)

1. Atherosclerosis - An inflammatory disease
2. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
3. Low-density lipoprotein oxidation and its pathobiological significance
4. The acute phase response
5. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
6. C-reactive protein as a cardiovascular risk factor. More then an epiphenomenon?
7. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
8. Production of C-reactive protein and risk of coronary events in stable and unstable angina
9. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function
10. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
11. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
12. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
17. HMG-CoA reductase inhibitors: A new class of anti-inflammatory drugs?
18. Statins do more than just lower cholesterol
19. Effect of statins on C-reactive protein in patients with coronary artery disease
20. Inhibition of proinflammatory cytokine production by pravastatin
21. Long-term effects of pravastatin on plasma concentration of C-reactive protein
22. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
23. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
24. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesives of monocytes isolated from patients with hypercholesterolemia
25. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
26. A study of the influence of various antirheumatic drug regimens on serum acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in rheumatoid arthritis
27. C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis
28. Inflammation, aspirin, and the risk of cardiovascular disease
29. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
30. Aspirin inhibits inducible nitric oxide synthase expression and tumor necrosis factor-α release by cultured smooth muscle cells